Spider Venom Peptides That Block Sodium Channels Could Lead to New Treatments for Pain and Epilepsy | Research

The takeaway

Spider venom contains a diverse class of cysteine knot peptides that selectively modulate voltage-gated sodium channels, and subtype-selective variants show therapeutic potential for chronic pain and epilepsy.

Mega-diverse peptide class targeting NaV channels
Spider venom cysteine knot peptides represent one of the largest and most structurally diverse families of sodium channel modulators found in nature, offering a rich library of potential drug leads with varying selectivity profiles.

What the researchers found

Spider venom-derived cysteine knot peptides modulate voltage-gated sodium channels (NaV) by binding to structural domains outside the channel pore, allosterically promoting either opening or closing. This mechanism produces diverse effects including modified pain responses, muscle paralysis, cardiac arrest, and numbness.

Critically, some of these peptides show subtype selectivity — they can distinguish between different NaV subtypes. This is therapeutically important because specific NaV subtypes (like NaV1.7 for pain, NaV1.1 for epilepsy) are implicated in different disorders. Subtype-selective spider venom peptides could theoretically target disease-relevant channels while sparing others, avoiding the broad side effects of current sodium channel drugs.

Why it matters

Current sodium channel-blocking drugs (like those used for pain and epilepsy) typically lack subtype selectivity, causing side effects by hitting multiple channel types throughout the body. Spider venom peptides have evolved over millions of years to target sodium channels with remarkable precision. Understanding their structure-activity relationships could enable the design of highly selective drugs for chronic pain, epilepsy, and other neurological conditions where current treatments fall short.

How the study worked

This is a review article that examines published research on the structure-activity relationships of spider venom cysteine knot peptides. The authors synthesize structural biology data (how the peptides fold and bind), electrophysiology studies (how they affect channel function), and pharmacological studies (their effects in disease models) to assess therapeutic potential.

What this study cannot tell us

As a review article, this paper does not present new experimental data. Most of the therapeutic potential discussed is based on preclinical studies, with very few spider venom peptides having advanced to clinical trials at the time of publication. The challenges of peptide drug delivery (most require injection), stability, and manufacturing costs are acknowledged but not deeply explored. Selectivity profiles of many discussed peptides remain incomplete.

How to read the evidence

This is a review article synthesizing preclinical and structural biology research on spider venom peptides. While comprehensive in scope, the therapeutic claims are largely based on in vitro and animal studies. No clinical trial data for the specific peptides discussed is presented.

When this study was published

Published in 2019, this review captures the field at an active period of venom peptide drug discovery. Since publication, several spider venom-derived peptides have continued advancing through preclinical development, and new structural data has further refined understanding of NaV channel-peptide interactions.

The bigger picture

Venom-derived peptides represent one of the most promising frontiers in drug discovery for neurological disorders. Several venom peptides have already reached clinical development (notably ziconotide from cone snails for pain). Spider venoms are particularly rich in sodium channel-targeting peptides, and advances in structural biology and peptide engineering are making it increasingly feasible to convert these natural toxins into selective therapeutics. This review maps the landscape of available spider venom peptide tools for sodium channel drug development.

Questions still open

Can the subtype selectivity of spider venom peptides be further enhanced through peptide engineering to create truly NaV-subtype-specific drugs?
What delivery strategies could make these peptides viable as orally available medications rather than injectable treatments?
Could combining structural insights from multiple spider species yield synthetic hybrid peptides with optimized therapeutic profiles?

Common questions

How can spider venom be turned into medicine?

Spider venoms contain peptides that have been refined by evolution to precisely target ion channels in the nervous system. Scientists isolate these peptides, study their structure to understand how they bind their targets, and then engineer modified versions that are selective for disease-relevant channels while being safe for therapeutic use. The peptide ziconotide, derived from cone snail venom, is already an approved pain drug — showing this approach works.

What are cysteine knot peptides and why are they special?

Cysteine knot peptides are small proteins with a distinctive structure where three pairs of cysteine amino acids form disulfide bonds that create a tight 'knot' in the center. This knot makes the peptides extremely stable and resistant to degradation, while the loops between the cysteine bonds can vary enormously — giving each peptide its unique ability to bind a specific molecular target. This combination of stability and target specificity makes them excellent drug candidates.

Read the original research

Structure-Function and Therapeutic Potential of Spider Venom-Derived Cysteine Knot Peptides Targeting Sodium Channels.

Frontiers in pharmacology, 10, 366

View on PubMed ↗Publisher’s paper ↗

Citation

Cardoso, Fernanda C; Lewis, Richard J. (2019). Structure-Function and Therapeutic Potential of Spider Venom-Derived Cysteine Knot Peptides Targeting Sodium Channels.. Frontiers in pharmacology, 10, 366. https://doi.org/10.3389/fphar.2019.00366